Leading ophthalmologists working alongside world-renowned scientists, engineers, and industry experts.
Management Team
Liane
Clamen, MD
Founder & CEO
Dr. Clamen is an ophthalmologist who earned her BA and MD at Harvard and completed her training at The Harvard Ophthalmology Residency Program at the Massachusetts Eye and Ear. She is the inventor of an Accommodating IOL, a punctal plug drug delivery system, and an anterior capsulotomy device.
Daniel Stanley, MS
Chief Operating Officer
Former Director of Intraocular Lens (IOL) Development at Alcon, Mr. Stanley has brought more than 30 IOL products from idea to market. With over 25 years of experience in the ophthalmology field, Mr. Stanley brings a wealth of experience to Adaptilens. He had lead roles on an R&D team that grew a medical device product line from $10M to $1B a year.
Earlier in his career, Mr. Stanley was an Air Force Officer and rocket propulsion engineer.
Brett Thomes, PhD
Chief Information and Technology Officer
Former Senior Director of Process Development at Alcon, Dr. Thomes has extensive experience and knowledge in R&D and Manufacturing of IOLs. An award-winning process development leader, Dr. Thomes has over 20 years of experience in the ophthalmology field and has led a global R&D team during his time at Alcon. Dr. Thomes has a track record of achievements in delivering a broad range of Class I/II/III medical devices to the market.
Adaptilens Board
Liane Clamen, MD
Chair, Adaptilens Board
Dr. Clamen is an ophthalmologist who earned her BA and MD at Harvard and completed her training at The Harvard Ophthalmology Residency Program at the Massachusetts Eye and Ear. She is the inventor of an Accommodating IOL, a punctal plug drug delivery system, and an anterior capsulotomy device.
Gianna Hoffman-Luca, PhD
Member, Adaptilens Board
Gianna is a Senior Principal at Perceptive Advisors and a Partner at Xontogeny, where she assists in the management of Perceptive Xontogeny Venture Funds’ investments in life sciences companies. Previously, Gianna built the competitive intelligence capabilities for gene therapy company Solid Biosciences and began her industry career as a patent agent with Choate, Hall & Stewart, LLP. Gianna earned her Ph.D. in Pharmacology from the University of Michigan Medical School and completed her M.S. and B.S. degrees at UC Santa Cruz in Chemistry.
William F. Shea, MBA
Member, Adaptilens Board
Mr. Shea has over 40 years of medical device leadership. He has served as Chief Executive Officer for three medical companies, and as a Board Member for over a dozen other medical companies. Mr. Shea began his career at The Kendal Company (now part of Medtronic) and later served as CEO of New Dimensions in Medicine, The Clinipad Corporation, and Med-Ecom. Bill has also consulted on numerous medical device transactions representing entrepreneurs with innovative technologies that fit in the portfolios of larger strategic medical companies.
Jamie Goldstein, MBA
Member, Adaptilens Board
Mr. Goldstein is Founding Partner at Pillar VC. He has spent over two decades working in venture capital. Prior to Pillar, Mr. Goldstein was an investing partner for 18 years at North Bridge Venture Partners.
Scientific Advisory Board
Mathew L
Becker, PhD
Member, Scientific Advisory Board
Dr. Becker is the Hugo L. Blomquist Distinguished Professor of Chemistry, Biomedical Engineering, Mechanical Engineering and Materials Science and Orthopaedic Surgery at Duke University. He is a Fellow of the National Academy of Inventors, the American Chemical Society, the Royal Society of Chemistry and the American Institute of Medical and Biological Engineering.
He is the author of more than 220 publications and has more than 100 issued and pending patents worldwide.
Thomas X
Neenan, PhD
Member, Scientific Advisory Board
A successful serial entrepreneur, Dr. Neenan is the Principal of Gray Door Partners LLC, a practice that develops university-based spinouts in science and biotech.
He is the author of 60+ publications and book chapters, and holds 45+ US and international patents.
Brian Levy,
OD, MSc
Member, Scientific Advisory Board
A proven leader in the field of Ophthalmology, Dr. Levy has extensive experience in Drug and Device Development. Dr. Levy was Chief Medical Officer of Bausch & Lomb and then Aerie Pharmaceuticals. He is currently Chief Executive Officer of OcuNexus Therapeutics, developing medications to treat chronic sight-threatening diseases.
He is a Clinical Professor in the Department of Ophthalmology at the University of Rochester’s School of Medicine and is the author of 50+ publications in peer-reviewed journals.
Elizabeth Yeu,
MD
Member, Scientific Advisory Board
Dr. Yeu is the current President of the American Society of Cataract and Refractive Surgery (ASCRS, 2023-2024). She is a partner at Virginia Eye Consultants, and an Assistant Professor of Ophthalmology at the Eastern Virginia Medical School. Dr. Yeu trained at the Baylor College of Medicine.
Dr Yeu has authored hundreds of publications and delivered hundreds of invited lectures. She is internationally recognized in her expert areas of refractive cataract surgery, complex lens-based surgeries, and ocular surface disease management. Dr. Yeu currently serves as the Chief Medical Advisor for Tarsus Pharmaceuticals.
Sheila Borboli-Gerogiannis,
MD, FACS
Member, Scientific Advisory Board
Dr. Borboli-Gerogiannis is a Harvard-trained ophthalmologist who specializes in cataract surgery and corneal disease. She serves as Site Director of the Mass Eye and Ear Longwood and is a member of the Comprehensive Ophthalmology and Cataract Consultation Service at the Mass Eye and Ear.
An Assistant Professor of Ophthalmology at Harvard Medical School, Dr. Borboli-Gerogiannis is a well-respected medical educator whose primary focus is teaching resident physicians how to perform cataract surgery.
Thomas Clinch,
MD
Member, Scientific Advisory Board
Dr. Clinch is the founding partner of Eye Doctors of Washington and has practiced ophthalmology for more than 30 years. He has performed over 40,000 LASIK and 20,000 cataract procedures. He was educated at Cornell, Jefferson Medical College, and the Wills Eye Hospital.
Throughout his award-winning career, Dr. Clinch has provided innovative, state-of-the-art care. He has served as an investigator in more than 30 clinical studies pertaining to LASIK, PRK, and a variety of IOLs. Dr. Clinch has presented 100+ professional presentations and has authored over 40 scientific articles
Cindy Chao,
MD, PhD
Member, Scientific Advisory Board
Dr. Chao earned her MD and PhD in molecular genetics from Harvard following her BS and MS from MIT. She completed her training at The Harvard Ophthalmology Residency Program at the Massachusetts Eye and Ear.
Dr. Chao was in clinical practice for 20 years, most recently at Ophthalmic Consultants of Boston. She specialized in cataract surgery and corneal conditions.
Board Observers
Jayanth Batchu, MEng
Board Observer
Jayanth is a Senior Analyst / Entrepreneur in Residence at Xontogeny, leveraging his diverse skill set to aid the due diligence efforts of the Xontogeny investment team. Jayanth is experienced in building up multiple biotech and medtech ideas including cell therapies (cancer & autoimmune), engineered enzymes & antibodies, core needle biopsy devices, infectious disease diagnostics, and urinary microvalves. Jayanth received an AB degree in Economics from Dartmouth College, a BE degree in Biomedical Engineering and MEng degree in Biological/Chemical Engineering from Dartmouth’s Thayer School of Engineering.
Robert ("Bob") Doris, JD, MBA
Board Observer
Mr. Doris is the Founding Partner of Accanto Partners, a seed-stage investor in startup companies. Previously, he founded and led Sonic Solutions from inception, as CEO (1986 – 2005) and later as Chairman (2005 – 2011). Sonic developed software and hardware tools for professional digital audio and digital video, with special focus on CD and DVD creation, and was recognized with a technical Emmy® award in 1996. Mr. Doris led Sonic’s successful IPO in 1994 and oversaw later developments as Sonic offered consumer tools for digital media creation including Roxio™ and Divx™ branded offerings, prior to the successful sale of Sonic to Rovi Corporation in 2011.
John Andres, JD
Board Observer
Mr. Andres is a patent attorney who has over 30 years of experience in the medical device industry in legal and business roles. He served as VP and Co-General Counsel at US Surgical Corporation, and as Director at K2M Inc.
We're making:
An intraocular lens that imitates the young, healthy, human lens so that patients will have near, intermediate, and distance vision without eyeglasses or contact lenses.
